Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients
Laure Sorber(University of Antwerp), Patrick Pauwels(University of Antwerp), Karen Zwaenepoel(University of Antwerp), Vanessa Deschoolmeester(University of Antwerp), Paul Van Schil(Antwerp University Hospital), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Jan P. van Meerbeeck(Antwerp University Hospital), Filip Lardon(University of Antwerp)
Cited by 156
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642